Dr. Sierk Poetting, COO of BioNTech

On July 7th, we welcomed Dr. Sierk Poetting, Chief Operating Officer of BioNTech, to our stage at TUM. Dr. Poetting shared insights into BioNTech’s pioneering work in cancer treatment.

While widely recognised for developing the world’s first approved mRNA COVID-19 vaccine, BioNTech’s original and continued focus is on oncology. Dr. Poetting discussed the company’s innovative therapeutic approaches designed to address the full continuum of cancer, including treatments for patients at high risk of relapse after early-stage tumour removal, as well as therapies targeting advanced and metastatic cancers.

The event offered a rare opportunity to hear directly from a leader of one of the world’s most impactful biotechnology companies about the future of personalised cancer medicine.

We also thank our moderator, Nick Wellen, for guiding the discussion with expertise and thoughtful questions.